Halo Pharms, LLC is a cannabis cultivation and extraction company based in Alaska. We are focused on producing high-quality cannabis products, including flower, concentrates, and edibles, with plans to expand into manufacturing various cannabis-infused products. Our operations are designed to be efficient, scalable, and environmentally sustainable, leveraging automation and renewable energy sources.

Our mission is to lead the cannabis industry in Alaska by producing premium, sustainably grown cannabis products. We aim to provide consumers with a variety of high-quality cannabis options while maintaining a commitment to innovation, operational efficiency, and environmental stewardship.

Halo Pharms differentiates itself through a phased growth strategy, focusing on automation and renewable energy to reduce costs and increase efficiency. Our commitment to environmental sustainability and the use of advanced technology positions us uniquely in the cannabis market. Additionally, our strategic reinvestment of profits allows for scalable growth with manageable risk.

Our growth strategy involves starting with a smaller-scale operation and gradually expanding by reinvesting profits. We plan to initially operate with two grow rooms and expand to six rooms as revenues grow. This phased expansion ensures operational efficiency and manageable risk while allowing us to scale up in response to market demand.

The cannabis market in Alaska is projected to grow at an annual rate of approximately 8.55% based on data from 2022 to 2024. Halo Pharms aims to capture a significant share of this growing market through our high-quality products and strategic expansion plans.

We plan to achieve profitability through a combination of high-quality production, competitive pricing, and efficient operations. Our use of automation and renewable energy reduces labor and utility costs, allowing us to offer competitively priced products while maintaining healthy profit margins. We also plan to reinvest profits into expanding our operations, further increasing our revenue potential.

• Year 1 (2024): Revenue: $36,600,000; Net Income: $15,847,529.93
• Year 2 (2025): Revenue: $50,000,000 (with expansion to four grow rooms)
• Year 3 (2026): Revenue: $70,000,000 (with expansion to six grow rooms and full automation)
• Year 4 (2027): Revenue: $100,000,000 (near full capacity)
• Year 5 (2028): Revenue: $120,000,000 (full capacity)

Our proposed ticker symbol for Halo Pharms on the NYSE is "HLOP".

We are seeking an initial funding of $1,900,000. This capital will be used for land acquisition, building construction, automation and equipment, and initial operating costs.

The initial investment will be allocated as follows:
• Land and Building: $662,500
• Automation and Equipment: $602,000
• Salaries and Initial Operating Costs: $165,000
• Other Essential Costs (Security, Utilities, etc.): $45,000

Like any investment, there are risks associated with the cannabis industry, including regulatory changes, market volatility, and operational challenges. However, Halo Pharms has a phased growth plan that allows for manageable risk, and our focus on automation and efficiency helps mitigate some of these risks.

Halo Pharms plans to incorporate solar panels and rooftop wind turbines to cover a significant portion of our energy needs. This not only reduces our carbon footprint but also decreases utility costs, contributing to our overall profitability.

Our long-term goals include becoming a leading cannabis producer in Alaska, expanding our product offerings, and achieving full operational capacity. We also aim to explore additional revenue streams through the extraction and manufacturing of cannabis-infused products.

Halo Pharms is led by Founder and CEO Van C. Adams, who brings significant industry experience and a vision for sustainable, high-quality cannabis production. Our team includes qualified cultivators, an outsourced CFO, and other key personnel dedicated to ensuring the company’s success.

If you’re interested in investing in Halo Pharms, please contact us through the information provided on our website. We can discuss investment opportunities, funding rounds, and how you can be a part of our growth.

While exact ROI will depend on market conditions and the company’s performance, our financial projections indicate strong profitability, especially as we scale operations. Investors can expect competitive returns as we expand and capture a larger market share.

Detailed financial information, including our profit and loss statements, balance sheets, and cash flow projections, is available on the "Stock Information" page of our website. For more specific inquiries, please contact our investor relations team.

Environmental sustainability is a core part of our operations. We use renewable energy sources, such as solar panels and wind turbines, and implement automation to reduce waste and conserve resources. Our goal is to minimize our environmental impact while maintaining high production standards.

While our current focus is on establishing a strong presence in the Alaskan market, we do have long-term aspirations to explore opportunities in other regions, particularly as the global cannabis market continues to expand.

We stay ahead of industry trends through continuous research and development, product diversification, and by closely monitoring market and regulatory changes. Our strategy includes expanding into new product lines, such as edibles and concentrates, to meet evolving consumer preferences.

Currently, Halo Pharms does not plan to pay dividends in the early stages of operations. Our focus is on reinvesting profits into expanding our production capacity and scaling our business. However, as the company grows and achieves stable profitability, the board of directors may consider implementing a dividend policy in the future.

Halo Pharms’ fiscal year ends on December 31st. This allows us to align our financial reporting with the calendar year, providing consistency and clarity for investors and stakeholders.

Halo Pharms’ first Annual Shareholder Meeting is planned for the second quarter of 2026, following the completion of our first full year of operations. The exact date and location will be announced closer to the event, and shareholders will receive formal invitations with detailed information.

The Annual Report for Halo Pharms will be available on our website after its release in 2026. Shareholders will be notified via email when the report is published. Physical copies of the report can also be requested by contacting our investor relations team.

Halo Pharms is committed to strong Environmental, Social Impact, and Governance (ESG) practices. Our ESG efforts include:

Environmental: Utilizing renewable energy sources such as solar panels and wind turbines, implementing sustainable cultivation practices, and reducing waste through automation and recycling programs.
Social Impact: Supporting local communities by creating jobs, participating in community outreach programs, and ensuring fair labor practices within our operations.
Governance: Maintaining transparency with investors, adhering to high standards of corporate governance, and ensuring that our operations comply with all relevant regulations and ethical guidelines.
We continually review and improve our ESG efforts to ensure that we contribute positively to the environment, society, and our stakeholders.